By IANS
Mumbai : Indian pharmaceutical major Ranbaxy Laboratories Ltd Monday said it had launched in the US pravastatin sodium tablets, meant for heart diseases.
Being the first-to-file, the company will enjoy a 180-day exclusivity for the pravastatin 80mg and benefit from the commercial gains during the period, it informed the Bombay Stock Exchange (BSE).
The annual sales for the tablets, used for prevention of several types coronary heart diseases, were $209 million, it said.
SUPPORT TWOCIRCLES
HELP SUPPORT INDEPENDENT AND NON-PROFIT MEDIA. DONATE HERE